AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32615613
Drug: Preventive carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive carbohydrate administration
Trial: 32615613
Drug: 2×10 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×10 g carbohydrates (muesli bars)
Trial: 32818917
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (ESK) plus oral antidepressant (OAD)
Trial: 38557430
Drug: Oral antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidepressant (OAD) plus placebo nasal spray (PBO)
Trial: 32283048
Drug: Virtual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Therapy (VT) for 8 weeks, approximately 45 minutes twice weekly on the Jintronix Rehabilitation System
Trial: 33218741
Drug: Traditional biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional biological valves
Trial: 34716201
Drug: SCO-267, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCO-267, a GPR40 Full Agonist
Trial: 33258102
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ticagrelor alone)
Trial: 38110196
Drug: Voclosporin (23.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voclosporin (23.7 mg twice daily)
Trial: 33022048
Drug: Brief behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief behavioral treatment for insomnia (BBTI)
Trial: 34915273
Drug: Total carbohydrate
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total carbohydrate (30-g increment)
Trial: 32815759
Drug: 20 µg hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg hepatitis B vaccine (IM20 group)
Trial: 32815759
Drug: 60 µg hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg hepatitis B vaccine (IM60 group)
Trial: 32297449
Drug: Background-medication-based individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background-medication-based individualized comparators (BMICs) including enalapril, valsartan, or placebo
Trial: 32750571
Drug: Overall anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall anticoagulation treatment
Trial: 32198409
Drug: G-CSF group
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF group (82 patients)
Trial: 35390539
Drug: Small bowel
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small bowel capsule endoscopy (SBCE) in patients with surgically altered gastric anatomy
Trial: 33884731
Drug: Barrier cream/micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barrier cream/micellar water
Trial: 32440101
Drug: Dupilumab 300mg
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab 300mg subcutaneously administered, added to standard intranasal steroid mometasone furoate, duration of treatment: 24 weeks (SINUS-24) or 52 weeks (SINUS-52) with varying injection frequency.
Trial: 35450525
Drug: Medium-term low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medium-term low-dose melatonin
Trial: 35450525
Drug: Exogenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous melatonin supplements
Trial: 35798596
Drug: i-PRF group
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-PRF group (intraarticular injection of injectable platelet-rich fibrin after arthrocentesis)
Trial: 33910617
Drug: Nelfinavir 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 750 mg orally, three times daily for 14 days
Trial: 35266669
Drug: Implant +
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant + connective tissue graft
Trial: 32163106
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel and nonpegylated liposomal doxorubicin (PM) with additional carboplatin (PMCb) for TNBC patients
Trial: 32163106
Drug: Sequential intense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intense dose‐dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC)
Trial: 32163106
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (ERBB2-negative, hormone receptor-positive BC)
Trial: 33965683
Drug: Telemedical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedical treatment
Trial: 33965683
Drug: On-site treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site treatment
Trial: 32842955
Drug: Midazolam administered
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam administered by a cardiologist
Trial: 33473017
Drug: Chloroquine nasal
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine nasal drops (0.03%) administered six times daily (0.5 ml/dose) for 10 days
Trial: 32703307
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy (DT)
Trial: 32448401
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day of prednisolone (PSL)
Trial: 32448401
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of prednisolone (PSL)
Trial: 35491532
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment (except for SGLT2 inhibitors)
Trial: 35025687
Drug: Compression plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression plus chemotherapy
Trial: 34749770
Drug: Topical low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical low-dose calcipotriol ointment (0.05 µg/g)
Trial: 32831097
Drug: Robot-assisted neurocognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted neurocognitive hand therapy
Trial: 32831097
Drug: Conventional neurocognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neurocognitive therapy
Trial: 35170837
Drug: Optimised minus
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised minus lens (OML) therapy, power ranged between -1.00D and -6.25D
Trial: 35170837
Drug: Optimised minus
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised minus lens (OML) therapy
Trial: 35941737
Drug: LNG implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG implant
Trial: 34587971
Drug: LNG implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG implant vs IUD
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 12.5 g kg‐1 diet
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 10.0-20.0 g kg‐1 diet
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 10.0-12.5 g kg‐1 diet
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 12.5-15.0 g kg‐1 diet
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 10.0 and 12.5 g kg‐1 diet
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 7.5-17.5 g kg‐1 diet
Trial: 32991991
Drug: Dietary isoleucine
RxNorm normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary isoleucine (Ile) at 10-12.5 g kg‐1 diet
Trial: 34242627
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (behavioral and pelvic floor muscle therapies with midurethral sling surgery)
Trial: 34242627
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (for women with Urogenital Distress Inventory irritative scores of ≥50th percentile)
Trial: 32757736
Drug: Cosmetic camouflage
RxNorm normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmetic camouflage (daily use for 12 weeks)
Trial: 32401072
Drug: Dance/movement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance/movement therapy (DMT)
Trial: 33931953
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg allopurinol
Trial: 34266844
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVA) monotherapy with sham photodynamic therapy (n=80)
Trial: 34266844
Drug: Aflibercept combined
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) (n=80)
Trial: 34229860
Drug: Fentanyl 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.5 mcg.kg‐1 (Group F)
Trial: 33166032
Drug: Propolis tablets
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis tablets at a dose of 250 mg twice daily for 4 months
Trial: 34753083
Drug: Cognitive control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive control treatment
Trial: 32768403
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) 4 mg every 8 hours for 3 days
Trial: 33291741
Drug: Trabectedin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin treatment
Trial: 34430349
Drug: H1299 lung
RxNorm normalized name: BEEF LUNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1299 lung cancer cell lysates (10 mg protein/vaccine) with Iscomatrix™ adjuvant via deep intradermal injection q 4 weeks ×6
Trial: 32516765
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with lavender oil (steam inhalation)
Trial: 32171318
Drug: Celebrex treatment
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celebrex treatment
Trial: 33681738
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg followed by misoprostol 400 μg
Trial: 33681738
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by misoprostol 400 μg
Trial: 34229364
Drug: DEHP-containing infusion
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEHP-containing infusion sets warmed with blood-fluid warmers
Trial: 34229364
Drug: DEHP-free infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEHP-free infusion sets warmed with blood-fluid warmers
Trial: 32679728
Drug: 120 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g/h carbohydrate intake (HIGH)
Trial: 32679728
Drug: 90 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g/h carbohydrate intake (MED)
Trial: 32679728
Drug: 60 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/h carbohydrate intake (LOW)
Trial: 32055002
Drug: PSA >0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA >0.2 to ≤4.0 ng/mL
Trial: 32055002
Drug: PSA >4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA >4.0 ng/mL
Trial: 35995418
Drug: Synbiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic treatment (Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, 32 billion colony forming units per day plus 3.2 g of inulin)
Trial: 616900538
Drug: Quince syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quince syrup (1 tablespoon/TDS) for 1 week
Trial: 616900538
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 tablets (20mg/TDS) for 1 week
Trial: 32270633
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received Xingnao Kaiqiao acupuncture at Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Jiquan (HT 1), Chize (LU 5), and Weizhong (BL 40), needles sustained for 30 min, same treatment frequency as observation group
Trial: 34419039
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to specialist due to oral problems
Trial: 32738935
Drug: live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: live attenuated intranasal pertussis vaccine BPZE1
Trial: 34881442
Drug: Hybrid surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid surface macro-design implants (HS)
Trial: 34881442
Drug: Conventional implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implants with moderately rough surface (RS)
Trial: 34284552
Drug: Sufentanil IN
RxNorm normalized name: sufentanil Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil IN 0.5 μg kg‐1
Trial: 34284552
Drug: Sufentanil IN
RxNorm normalized name: sufentanil Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil IN 0.25 μg kg‐1
Trial: 34284552
Drug: IV midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV midazolam 0.04 mg kg‐1 and IN 0.9% NaCl (placebo)
Trial: 35958557
Drug: Marine long
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine long chain omega-3 polyunsaturated fatty acids (1.1 g EPA + 0.8 g DHA daily)
Trial: 33636027
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) without enzalutamide (Cohort 1)
Trial: 33636027
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) and enzalutamide (Cohort 2)
Trial: 33839115
Drug: Indoor air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor air quality measurements of volatile organic compounds (VOCs) and inorganic gaseous pollutants using passive samplers over 7 days.
Trial: 38344045
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day)
Trial: 35968476
Drug: Isha yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isha yoga practice (3 minutes daily)
Trial: 35968476
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator (15 minutes daily reading)
Trial: 35968476
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator (15 minutes daily reading)
Trial: 32818346
Drug: Dexamethasone intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intraocular suspension 9%
Trial: 32818346
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate 1%
Trial: 35403793
Drug: Cotadutide (50‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide (50‐300 μg, once‐daily subcutaneous)
Trial: 35091036
Drug: Intraosseous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous regional administration (IORA) of 500 mg vancomycin
Trial: 35842199
Drug: High-Dose Interferon-α2b
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-Dose Interferon-α2b (HDI)
Trial: 33449378
Drug: Functional Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Family Therapy (FFT) in addition to Treatment-As-Usual (TAU)
Trial: 34436521
Drug: Cisplatin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (70 mg/m2 on day 1) and Gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Trial: 34436521
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2 on day 1), Gemcitabine (875 mg/m2 on days 1 and 8), and Berzosertib (90 mg/m2 on days 2 and 9 of a 21-day cycle)
Trial: 34030899
Drug: Cold pack
RxNorm normalized name: CVS Cold Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold pack kept in the refrigerator applied to the area above the IV catheter before drug infusion
Trial: 34030899
Drug: Routine drug
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drug infusion without cold application in the control group
Trial: 32167976
Drug: Iloprost (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (20 μg) inhaled
Trial: 32167976
Drug: Saline inhaled
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhaled (Control)
Trial: 32913154
Drug: Intra-rectal xylocaine
RxNorm normalized name: Xylocaine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-rectal xylocaine gel (10 mls)
Trial: 32124566
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 0.3 g/kg SB
Trial: 32124566
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 0.6 g/kg SB
Trial: 32124566
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 1.2 g/kg SB
Trial: 34475868
Drug: Planned treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned treatment interruption
Trial: 33891472
Drug: Atezolizumab 1,200
RxNorm normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1,200 mg plus platinum-based chemotherapy (paclitaxel plus carboplatin) and bevacizumab 15 mg/kg
Trial: 33891472
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus platinum-based chemotherapy (paclitaxel plus carboplatin) and bevacizumab 15 mg/kg
Trial: 35768286
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) plus levocabastine nasal spray
Trial: 35768286
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) plus placebo nasal spray
Trial: 34446497
Drug: CytoSorb therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoSorb therapy (continuous for at least 24 hours, adsorber device changed every 12 hours)
Trial: 34446497
Drug: CytoSorb therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoSorb therapy (continuous for at least 24 hours, adsorber device changed every 24 hours)
Trial: 32386466
Drug: Group-based multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based multimodal physical therapy
Trial: 32386466
Drug: Primary-care physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary-care physical therapy
Trial: 37528476
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Er:YAG and long-pulsed Nd:YAG lasers
Trial: 37528476
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser therapy only
Trial: 35141517
Drug: Topical ethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ethyl chloride spray (ECS)
Trial: 35141517
Drug: Subcutaneous 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 1% lidocaine injection (LI)
Trial: 36094783
Drug: Quarter-dose combination
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter-dose combination of amlodipine, telmisartan, and chlorthalidone
Trial: 36094783
Drug: Half-dose combination
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose combination of amlodipine, telmisartan, and chlorthalidone